4 May 2024 • In RA patients on anti‐inflammatory therapy, researchers found that despite a reduction in inflammatory markers like high‐sensitivity CRP (hsCRP) & interleukin‐1b, there was no significant improvement in myocardial flow reserve (MFR).

Nearly half had coronary microvascular dysfunction at baseline, yet neither MFR nor high‐sensitivity cardiac troponin T (hs‐cTnT) levels changed significantly post treatment initiation.

However, a modest reduction in interleukin‐1b and no other inflammatory pathways was correlated with a reduction in subclinical myocardial injury.

Source: JAHA | Read full story